Literature DB >> 27861902

The molecular basis of breast cancer pathological phenotypes.

Yujing J Heng1,2, Susan C Lester3, Gary Mk Tse4, Rachel E Factor5, Kimberly H Allison6, Laura C Collins1,2, Yunn-Yi Chen7, Kristin C Jensen6,8, Nicole B Johnson1,2, Jong Cheol Jeong1,2, Rahi Punjabi1,2, Sandra J Shin9, Kamaljeet Singh10, Gregor Krings7, David A Eberhard11, Puay Hoon Tan12, Konstanty Korski13, Frederic M Waldman14, David A Gutman15, Melinda Sanders16, Jorge S Reis-Filho17, Sydney R Flanagan1,2, Deena Ma Gendoo18,19, Gregory M Chen18, Benjamin Haibe-Kains18,19, Giovanni Ciriello20, Katherine A Hoadley21, Charles M Perou11,21, Andrew H Beck1,2.   

Abstract

The histopathological evaluation of morphological features in breast tumours provides prognostic information to guide therapy. Adjunct molecular analyses provide further diagnostic, prognostic and predictive information. However, there is limited knowledge of the molecular basis of morphological phenotypes in invasive breast cancer. This study integrated genomic, transcriptomic and protein data to provide a comprehensive molecular profiling of morphological features in breast cancer. Fifteen pathologists assessed 850 invasive breast cancer cases from The Cancer Genome Atlas (TCGA). Morphological features were significantly associated with genomic alteration, DNA methylation subtype, PAM50 and microRNA subtypes, proliferation scores, gene expression and/or reverse-phase protein assay subtype. Marked nuclear pleomorphism, necrosis, inflammation and a high mitotic count were associated with the basal-like subtype, and had a similar molecular basis. Omics-based signatures were constructed to predict morphological features. The association of morphology transcriptome signatures with overall survival in oestrogen receptor (ER)-positive and ER-negative breast cancer was first assessed by use of the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset; signatures that remained prognostic in the METABRIC multivariate analysis were further evaluated in five additional datasets. The transcriptomic signature of poorly differentiated epithelial tubules was prognostic in ER-positive breast cancer. No signature was prognostic in ER-negative breast cancer. This study provided new insights into the molecular basis of breast cancer morphological phenotypes. The integration of morphological with molecular data has the potential to refine breast cancer classification, predict response to therapy, enhance our understanding of breast cancer biology, and improve clinical management. This work is publicly accessible at www.dx.ai/tcga_breast.
Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  PAM50; TCGA; bioinformatics; epithelial tubule formation; genomics; histological grade; mRNA

Mesh:

Substances:

Year:  2016        PMID: 27861902      PMCID: PMC5499709          DOI: 10.1002/path.4847

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  117 in total

1.  Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer.

Authors:  Torsten Stein; Karen N Price; Joanna S Morris; Victoria J Heath; Roderick K Ferrier; Alexandra K Bell; Marie-Anne Pringle; René Villadsen; Ole W Petersen; Guido Sauter; Gareth Bryson; Elizabeth A Mallon; Barry A Gusterson
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

2.  Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Authors:  John Stagg; Sherene Loi; Upulie Divisekera; Shin Foong Ngiow; Helene Duret; Hideo Yagita; Michele W Teng; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

3.  pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers.

Authors:  B E Gillesby; T R Zacharewski
Journal:  Breast Cancer Res Treat       Date:  1999-08       Impact factor: 4.872

4.  New insights of CTLA-4 into its biological function in breast cancer.

Authors:  H Mao; L Zhang; Y Yang; W Zuo; Y Bi; W Gao; B Deng; J Sun; Q Shao; X Qu
Journal:  Curr Cancer Drug Targets       Date:  2010-11       Impact factor: 3.428

Review 5.  Chronic inflammation and cancer: the role of the mitochondria.

Authors:  David W Kamp; Emily Shacter; Sigmund A Weitzman
Journal:  Oncology (Williston Park)       Date:  2011-04-30       Impact factor: 2.990

6.  The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors:  Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

7.  Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast.

Authors:  David P Arps; Patrick Healy; Lili Zhao; Celina G Kleer; Judy C Pang
Journal:  Breast Cancer Res Treat       Date:  2013-03-28       Impact factor: 4.872

8.  Cancer Digital Slide Archive: an informatics resource to support integrated in silico analysis of TCGA pathology data.

Authors:  David A Gutman; Jake Cobb; Dhananjaya Somanna; Yuna Park; Fusheng Wang; Tahsin Kurc; Joel H Saltz; Daniel J Brat; Lee A D Cooper
Journal:  J Am Med Inform Assoc       Date:  2013-07-25       Impact factor: 4.497

Review 9.  Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.

Authors:  Dirce M Carraro; Eliana V Elias; Victor P Andrade
Journal:  Biosci Rep       Date:  2014-02-01       Impact factor: 3.840

10.  E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.

Authors:  C B Vos; A M Cleton-Jansen; G Berx; W J de Leeuw; N T ter Haar; F van Roy; C J Cornelisse; J L Peterse; M J van de Vijver
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  43 in total

1.  Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.

Authors:  Sanghoon Lee; Yiheng Hu; Suet Kee Loo; Ying Tan; Rohit Bhargava; Michael T Lewis; Xiao-Song Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-22       Impact factor: 11.205

2.  The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network.

Authors:  Yujing J Heng; Susan E Hankinson; Jun Wang; Ludmil B Alexandrov; Christine B Ambrosone; Victor P de Andrade; Adam M Brufsky; Fergus J Couch; Tari A King; Francesmary Modugno; Celine M Vachon; A Heather Eliassen; Rulla M Tamimi; Peter Kraft
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-01-13       Impact factor: 4.254

3.  Cancer subtypes in aetiological research.

Authors:  Lorenzo Richiardi; Francesco Barone-Adesi; Neil Pearce
Journal:  Eur J Epidemiol       Date:  2017-05-11       Impact factor: 8.082

4.  The Digital Slide Archive: A Software Platform for Management, Integration, and Analysis of Histology for Cancer Research.

Authors:  David A Gutman; Mohammed Khalilia; Sanghoon Lee; Michael Nalisnik; Zach Mullen; Jonathan Beezley; Deepak R Chittajallu; David Manthey; Lee A D Cooper
Journal:  Cancer Res       Date:  2017-11-01       Impact factor: 12.701

Review 5.  Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.

Authors:  Adam M Brufsky; Maura N Dickler
Journal:  Oncologist       Date:  2018-01-19

6.  Proceedings of the fourth international molecular pathological epidemiology (MPE) meeting.

Authors:  Peter T Campbell; Christine B Ambrosone; Timothy R Rebbeck; Shuji Ogino; Reiko Nishihara; Hugo J W L Aerts; Melissa Bondy; Nilanjan Chatterjee; Montserrat Garcia-Closas; Marios Giannakis; Jeffrey A Golden; Yujing J Heng; N Sertac Kip; Jill Koshiol; X Shirley Liu; Camila M Lopes-Ramos; Lorelei A Mucci; Jonathan A Nowak; Amanda I Phipps; John Quackenbush; Robert E Schoen; Lynette M Sholl; Rulla M Tamimi; Molin Wang; Matty P Weijenberg; Catherine J Wu; Kana Wu; Song Yao; Kun-Hsing Yu; Xuehong Zhang
Journal:  Cancer Causes Control       Date:  2019-05-08       Impact factor: 2.506

7.  Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies.

Authors:  Lisa Han; Alexander J Gallan; Gary D Steinberg; Randy F Sweis; Gladell P Paner
Journal:  Hum Pathol       Date:  2020-09-26       Impact factor: 3.466

8.  PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts.

Authors:  Kevin H Kensler; Venkat N Sankar; Jun Wang; Xuehong Zhang; Christopher A Rubadue; Gabrielle M Baker; Joel S Parker; Katherine A Hoadley; Andreea L Stancu; Michael E Pyle; Laura C Collins; David J Hunter; A Heather Eliassen; Susan E Hankinson; Rulla M Tamimi; Yujing J Heng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-12-27       Impact factor: 4.254

9.  Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.

Authors:  Yujing J Heng; Jun Wang; Thomas U Ahearn; Susan B Brown; Xuehong Zhang; Christine B Ambrosone; Victor Piana de Andrade; Adam M Brufsky; Fergus J Couch; Tari A King; Francesmary Modugno; Celine M Vachon; Natalie C DuPre; Montserrat Garcia-Closas; Melissa A Troester; David J Hunter; A Heather Eliassen; Rulla M Tamimi; Susan E Hankinson; Andrew H Beck
Journal:  Breast Cancer Res Treat       Date:  2018-11-01       Impact factor: 4.872

Review 10.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.